Bladder Cancer to get Evaluated for Proton Pump Inhibitors

Release Date: 21-Nov-2020

A recent study is focused towards the patients who have been suffering from advanced urothelial carcinoma. As per the researchers who conducted the research study, proton pump inhibitor could be used as a negative prognostic marker in the patients when treated with only immune checkpoint inhibitor (ICI) therapy atezolizumab (Tecentriq). It was observed by the researchers that the use of proton pump inhibitor was responsible for affecting the extent of the immune checkpoint inhibitors.


The respective clinical trial conducted by the researchers was a single-arm trial of atezolizumab i.e. IMvigor210 trial which involved 429 patients and IMvigor211 trial which included 931 patients (atezolizumab versus chemotherapy). The primary aim of the researchers involved was to study about proton pump inhibitor use, overall survival rate and progression free survival in the cancer patients. It was observed that the enrolled patients who received proton pump inhibitor were associated with worse overall survival with atezolizumab. It was concluded from the clinical research study that patients given atezolizumab in both the PD-L1 IC2/3 population and the total population received potential benefits when compared with the participants that were PPI users. The next aim of the researchers is to identify the influence of PPI on ICI efficiency in other cancer types, first-line ICI use, combination ICI use, and combination chemotherapy approaches.

Need custom market research solution? We can help you with that too.